DEFA14A: Masimo Defends Strategy Amidst Proxy Fight, Highlights Innovation and Legal Battles

Masimo launches a website to defend its strategy in connection with its 2024 Annual Meeting of Stockholders, highlighting its innovations, legal battles with Apple, and forward-looking statements regarding a potential separation of its consumer business.

Summary

• Masimo has launched a website to communicate with stockholders in connection with its 2024 Annual Meeting.
• The company highlights its 35-year history of innovation in medical biosensing.
• Masimo emphasizes its efforts to combat the U.S. opioid crisis, which claims over 80,000 lives each year.
• The company received FDA clearance for its Stork baby monitoring system for over-the-counter use in May 2024.
• Masimo's Stork system monitors a baby's oxygen saturation level (SpO2), pulse rate (PR), and skin temperature.
• Masimo is recognized as one of Fast Company's Most Innovative Companies in North America for 2024.
• The company received FDA clearance for Opioid Halo, an opioid overdose-and-prevention-alert system.
• Masimo is engaged in an ongoing patent dispute with Apple, which has cost the company around $100 million.
• The U.S. International Trade Commission ruled that Apple violated Masimo's patents, leading to a temporary ban on some Apple Watch sales.
• Masimo's CEO, Joe Kiani, has vowed to fight on and will not settle with Apple unless they pay for his technology and change how they interact with smaller companies.
• For the first nine months of 2023, Masimo garnered $1.5 billion in revenue, a 5.7% increase from a year earlier.
• The company is considering a potential separation of its consumer business to maximize shareholder value.
• Masimo faces uncertainties regarding the potential separation of its consumer business and future actions by Politan in its nomination of director candidates.

Sentiment

Score: 6

Explanation: The document presents a mixed sentiment. While it highlights Masimo's innovations and achievements, it also acknowledges the challenges of the Apple legal battle and the uncertainties surrounding the potential separation of the consumer business. The ongoing proxy fight adds another layer of complexity.

Positives

• Masimo has a long history of innovation in medical biosensing.
• The company has received FDA clearance for several new products, including Stork and Opioid Halo.
• Masimo is recognized as one of Fast Company's Most Innovative Companies in North America.
• The company is experiencing revenue growth, with a 5.7% increase in the first nine months of 2023.
• Masimo has a track record of successfully defending its intellectual property in patent disputes.
• Masimo prevailed in a seven-year patent spat with Nellcor in 2006, resulting in nearly $800 million in damages and royalties.
• In 2016, Masimo beat Royal Philips in another patent-infringement case, with Philips paying out $300 million and agreeing to incorporate Masimo's technology.

Negatives

• Masimo is engaged in an expensive and ongoing patent dispute with Apple, costing the company around $100 million.
• The company faces uncertainties regarding the potential separation of its consumer business.
• Masimo faces potential cost and management distraction attendant to Politans nomination of director nominees at the 2024 Annual Meeting.
• The mounting legal bills from the Apple dispute have eaten into the company's profits.

Risks

• Uncertainties regarding a potential separation of Masimo's consumer business.
• Uncertainties regarding future actions that may be taken by Politan in furtherance of its nomination of director candidates for election at the 2024 Annual Meeting.
• The potential cost and management distraction attendant to Politan's nomination of director nominees at the 2024 Annual Meeting.
• The ongoing patent dispute with Apple could continue to be costly and time-consuming.
• The company's success depends on its ability to continue innovating and developing new products.
• The company faces competition from other medical device manufacturers.

Future Outlook

Masimo is considering a potential separation of its consumer business to maximize shareholder value. The company plans to release new alarm features for the Stork App this summer.

Management Comments

• Joe Kiani: To truly make a difference, you have to commit yourself. You have to be obsessed with what you do.
• Joe Kiani: Justice isnt just blind but very slow. Its painful. Its an ugly thing to go through. Its like war.
• Joe Kiani: No one is standing up to them (Apple). If I can do it, it might change Apple for the better.
• Joe Kiani: I feel like I have to do this. If I can change the most powerful company in the world from continuing to act badly, thatll have more impact on the world than anything else Im doing.

Industry Context

Masimo's dispute with Apple highlights the challenges smaller companies face when competing with tech giants over intellectual property. The company's focus on medical biosensing and patient monitoring aligns with the growing trend of remote patient monitoring and telehealth.

Comparison to Industry Standards

• Masimo's pulse oximetry technology competes with that of companies like Medtronic (formerly Nellcor) and Philips.
• The company's legal battle with Apple is similar to other cases where smaller companies have accused Apple of patent infringement.
• Masimo's revenue growth of 5.7% in the first nine months of 2023 is comparable to the growth rates of other medical device companies.
• The $100 million spent on the Apple legal battle is a significant amount, especially when compared to Masimo's $144 million profit in 2022.

Legal Proceedings

• Masimo is engaged in an ongoing patent dispute with Apple.
• The U.S. International Trade Commission ruled that Apple violated Masimo's patents.
• Masimo sued Apple in January 2020 over allegations that Apple stole its trade secrets.
• Masimo prevailed in a seven-year patent spat with Nellcor in 2006.
• In 2016, Masimo beat Royal Philips in another patent-infringement case.

Stakeholder Impact

• Shareholders: The potential separation of the consumer business could impact shareholder value.
• Employees: The ongoing patent dispute with Apple and the potential separation of the consumer business could impact employee morale and job security.
• Customers: Masimo's innovations, such as Stork and Opioid Halo, could improve patient outcomes and provide better healthcare solutions.
• Suppliers: Masimo's growth and product development could lead to increased demand for suppliers.
• Creditors: The company's financial performance and legal proceedings could impact its creditworthiness.

Next Steps

• Masimo will hold its 2024 Annual Meeting of Stockholders.
• The company will continue to pursue its patent dispute with Apple.
• Masimo expects to release an update to its Stork App this summer.
• The company will consider the potential separation of its consumer business.

Key Dates

Keywords

Masimo, Apple, patent dispute, Stork, Opioid Halo, FDA clearance, Joe Kiani, proxy fight, innovation, medical biosensing, consumer business separation